McAdam LLC Sells 377 Shares of Agilent Technologies, Inc. (NYSE:A)

McAdam LLC lessened its holdings in Agilent Technologies, Inc. (NYSE:A) by 13.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,450 shares of the medical research company’s stock after selling 377 shares during the period. McAdam LLC’s holdings in Agilent Technologies were worth $341,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. OFI Invest Asset Management purchased a new position in Agilent Technologies during the third quarter valued at $25,000. MV Capital Management Inc. increased its holdings in shares of Agilent Technologies by 120.7% in the fourth quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after purchasing an additional 105 shares during the last quarter. Baystate Wealth Management LLC lifted its position in shares of Agilent Technologies by 107.3% in the fourth quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock worth $36,000 after buying an additional 133 shares in the last quarter. Column Capital Advisors LLC boosted its stake in Agilent Technologies by 1,111.1% during the third quarter. Column Capital Advisors LLC now owns 327 shares of the medical research company’s stock valued at $37,000 after buying an additional 300 shares during the last quarter. Finally, Rosenberg Matthew Hamilton grew its holdings in Agilent Technologies by 51.1% during the 4th quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock valued at $39,000 after buying an additional 96 shares in the last quarter.

Insiders Place Their Bets

In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total value of $239,315.72. Following the sale, the director now directly owns 54,976 shares of the company’s stock, valued at $7,935,235.84. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, SVP Philip Binns sold 2,827 shares of Agilent Technologies stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $147.54, for a total transaction of $417,095.58. Following the completion of the transaction, the senior vice president now directly owns 9,997 shares of the company’s stock, valued at approximately $1,474,957.38. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total transaction of $239,315.72. Following the completion of the transaction, the director now owns 54,976 shares of the company’s stock, valued at $7,935,235.84. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,610 shares of company stock worth $9,220,333.

Agilent Technologies Trading Up 1.3 %

NYSE A opened at $139.59 on Tuesday. The stock has a market cap of $40.91 billion, a PE ratio of 33.24, a PEG ratio of 4.17 and a beta of 1.11. Agilent Technologies, Inc. has a 12 month low of $96.80 and a 12 month high of $151.58. The company’s 50-day moving average price is $141.69 and its 200-day moving average price is $131.02. The company has a current ratio of 2.68, a quick ratio of 2.04 and a debt-to-equity ratio of 0.41.

Agilent Technologies (NYSE:A) last issued its earnings results on Tuesday, February 27th. The medical research company reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. The business had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same period in the prior year, the firm earned $1.37 EPS. The company’s revenue for the quarter was down 5.5% compared to the same quarter last year. Equities research analysts forecast that Agilent Technologies, Inc. will post 5.5 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd were given a dividend of $0.236 per share. This represents a $0.94 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date was Monday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.38%.

Analysts Set New Price Targets

Several analysts have recently issued reports on A shares. Oppenheimer upped their price objective on Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a report on Tuesday, March 26th. Barclays upped their price target on shares of Agilent Technologies from $125.00 to $135.00 and gave the company an “underweight” rating in a research note on Wednesday, April 10th. Evercore ISI lifted their price objective on shares of Agilent Technologies from $132.00 to $145.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Stifel Nicolaus upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and upped their target price for the company from $145.00 to $163.00 in a research report on Friday, April 5th. Finally, Citigroup lifted their price target on Agilent Technologies from $130.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $141.29.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.